Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Primordial cardiovascular prevention draws closer

Key clinical point: When it comes to cardiovascular risk, genetics is not destiny.

Major finding: High genetic risk for cardiovascular disease is largely canceled by low lifetime exposure to LDL cholesterol and SBP.

Study details: This Mendelian randomization study included 445,774 participants in the UK Biobank.

Disclosures: Dr. Ference reported financial interests in Merck, Amgen, Regeneron, Sanofi, Novartis, Pfizer, Eli Lilly, NovoNordisk, The Medicines Company, Mylan, Daiichi Sankyo, Silence Therapeutics, Ionis Pharmaceuticals, dalCOR, CiVi Pharma, KrKa Pharmaceuticals, Medtronic, and Celera.


Ference BA. ACC 20. Featured Clinical Research 1 session.